<DOC>
	<DOC>NCT02094365</DOC>
	<brief_summary>This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.</brief_summary>
	<brief_title>A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Age 18 to 45 years, inclusive. In good health with no history of major medical conditions A total body weight â‰¥ 50 kg and a body mass index (BMI) of &gt; 18kg/m2. Acute or chronic medical illness Positive for Human Immunodeficiency Virus, Hepatitis B or C Nose or nasopharynx abnormalities Abnormal lung function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>